Cytotoxic T-cell Activation via MHC Class I/II Presentation (CTL Activation)

Cytotoxic T-cell activation via MHC class I/II presentation is a critical process in adaptive immunity where cytotoxic T lymphocytes (CTLs) are activated to recognize and destroy infected or abnormal cells. This involves antigen processing and presentation on MHC molecules, T cell receptor (TCR) recognition, co-stimulation, and the release of cytotoxic molecules like perforin and granzymes. While MHC Class I presentation primarily activates CD8+ T cells to eliminate infected cells, MHC Class II presentation on antigen-presenting cells leads to CD4+ T cell activation, which indirectly supports CTL responses. The process is essential for defense against intracellular pathogens and tumor surveillance, but dysregulation can lead to autoimmunity or immunodeficiency.

Other names

CD8+ T cell activationT cell mediated cytotoxicityMHC Class I antigen presentationMHC Class II antigen presentationCytotoxic T Lymphocyte Activation

Varies depending on the specific drug or therapeutic approach. Immunosuppressants inhibit T cell activation. Checkpoint inhibitors enhance T cell activity. Adjuvants enhance antigen presentation and co-stimulation.